Tag : QoL

CONFERENCE UPDATE

Iptacopan delivers sustained QoL gains and symptom control in PNH: 48-week findings from the APPLY-PNH and APPOINT-PNH trials
Persistent hemolysis and anemia in paroxysmal nocturnal hemoglobinuria (PNH) can significantly impair health-related quality of life (HRQoL) and lead to debilitating symptoms, with fatigue recognized as the most disabling. Despite advancements, a need remains to address these challenges effectively.
CONFERENCE UPDATE

Unmet needs persist in hemophilia A management: Findings from a real-world analysis of the Adelphi Hemophilia Disease Specific ProgrammeTM
For individuals with hemophilia A, lifelong prophylactic treatment with FVIII replacement therapies or non-factor therapies (NFTs) is the standard of care. Despite advancements in treatment, bleeding episodes persist, significantly impacting physical health and quality of life (QoL).
CONFERENCE UPDATE

Symptom reduction and QoL improvement in CRSwNP patients with mepolizumab: Results from the phase 3 SYNAPSE trial
Chronic rhinosinusitis with nasal polyp (CRSwNP) is a chronic disease characterized by elevated interleukin 5 (IL-5) levels and is often associated with severe sinonasal symptoms and nasal obstruction. Mepolizumab is a humanized anti-IL-5 antibody approved as an add-on medication for CRSwNP. In the pivotal phase 3 SYNAPSE study, mepolizumab demonstrated improvement in sinonasal outcomes and reduction in corticosteroid use or surgery need in patients with CRSwNP. However, its effect on the number of low-symptom/symptom-free or symptom-reduced days remained unclear.